Exelixis, Inc. (EXEL)
| Market Cap | 12.54B +12.5% |
| Revenue (ttm) | 2.38B +3.3% |
| Net Income | 833.42M +29.5% |
| EPS | 3.02 +37.2% |
| Shares Out | 251.36M |
| PE Ratio | 16.51 |
| Forward PE | 15.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,414,168 |
| Open | 49.00 |
| Previous Close | 48.67 |
| Day's Range | 48.88 - 50.20 |
| 52-Week Range | 33.76 - 51.63 |
| Beta | 0.38 |
| Analysts | Buy |
| Price Target | 49.06 (-1.68%) |
| Earnings Date | May 5, 2026 |
About EXEL
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]
Financial Performance
In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price target is $49.06, which is a decrease of -1.68% from the latest price.
News
Exelixis Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Zanzalintinib is advancing through multiple pivotal trials in CRC and RCC, aiming to establish new standards of care with robust data and tailored dosing strategies. The pipeline emphasizes biotherapeutics, with a disciplined approach to prioritization and data disclosure.
Exelixis Transcript: RBC Capital Markets Global Healthcare Conference 2026
CABO continues to lead in RCC and NETs, supported by strong market share and Salesforce expansion. Zanza is positioned for future leadership with pivotal trials in CRC and RCC, a robust launch strategy, and collaborative development efforts. Approval and launch preparations are on track for late 2024.
Exelixis announces clinical development collaboration with Merck
Exelixis (EXEL) announced that the company has entered into a clinical development collaboration with Merck (MRK), known as MSD outside of the United States and Canada, to supply Keytrude Qlex…
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United St...
Exelixis Transcript: Bank of America Global Healthcare Conference 2026
Capital allocation remains flexible, balancing share buybacks and R&D based on evolving data and opportunities. CABO will continue to be prioritized while zanza is positioned as the next growth driver, with multiple pivotal trials and commercial expansion into new oncology segments.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities...
Exelixis price target raised to $56 from $54 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Exelixis (EXEL) to $56 from $54 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
Exelixis price target raised to $50 from $49 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $50 from $49 and keeps an Equal Weight rating on the shares after the company shared updates across its…
Exelixis price target raised to $47 from $44 at Stifel
Stifel raised the firm’s price target on Exelixis (EXEL) to $47 from $44 and keeps a Hold rating on the shares.
Exelixis price target raised to $55 from $51 at TD Cowen
TD Cowen raised the firm’s price target on Exelixis (EXEL) to $55 from $51 and keeps a Buy rating on the shares. The firm said new combo studies for zanza…
Exelixis Earnings Call Transcript: Q1 2026
Q1 2026 saw robust revenue and net income growth, record CABOMETYX patient starts, and strong market share gains. ZANZA's NDA for CRC is under review, with multiple pivotal trials advancing across tumor types. A new $750M share repurchase plan was authorized.
Exelixis Earnings release: Q1 2026
Exelixis released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Exelixis Quarterly report: Q1 2026
Exelixis has published its Q1 2026 quarterly earnings report on May 5, 2026.
Exelixis Slides: Q1 2026
Exelixis has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2026, provided an update on progress toward achieving key corporate objectives...
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 ...
Exelixis price target raised to $45 from $44 at Barclays
Barclays raised the firm’s price target on Exelixis (EXEL) to $45 from $44 and keeps an Equal Weight rating on the shares. The firm adjusted ratings and targets in the…
Exelixis Proxy statement: Proxy filing
Exelixis filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Exelixis Proxy statement: Proxy filing
Exelixis filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.
Exelixis Proxy statement: Proxy filing
Exelixis filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.
Exelixis Transcript: Barclays 28th Annual Global Healthcare Conference
CABOMETYX continues to drive strong financial performance and strategic growth, with Zanzalintinib advancing through pivotal studies and a diversified pipeline targeting solid tumors. The company is expanding its commercial reach and focusing on assets that can redefine standards of care.
Exelixis Transcript: The Citizens Life Sciences Conference 2026
Revenue reached $2.123 billion with guidance for $2.4 billion in 2026, driven by RCC and NET launches. Zanza is positioned for a $5 billion+ opportunity with seven pivotal studies, while STELLAR-303 and -304 aim to set new standards in CRC and non-clear cell RCC.
Exelixis Transcript: Leerink Global Healthcare Conference 2026
Recent ASCO GU data in RCC showed PFS benefit but no significant OS improvement, influencing a shift toward sequential treatment strategies and highlighting the importance of quality of life and toxicity profiles. Key trials like LITESPARK-033 and STELLAR-304 aim to redefine standards in RCC, while STELLAR-303 in CRC demonstrated a survival advantage, supporting strong growth projections for 2026.
Exelixis Transcript: TD Cowen 46th Annual Health Care Conference
The discussion highlighted a strategic shift toward building multiple oncology franchises, with zanzalintinib poised for launch and a robust pipeline targeting RCC, CRC, and other cancers. Strong financial performance, ongoing pivotal trials, and disciplined capital allocation support long-term growth.
Exelixis price target lowered to $43 from $46 at RBC Capital
RBC Capital lowered the firm’s price target on Exelixis (EXEL) to $43 from $46 and keeps a Sector Perform rating on the shares. The firm notes that competitive pressures could…